Nabuser
Brand names,
Nabuser
Analogs
Nabuser
Brand Names Mixture
Nabuser
Chemical_Formula
C12H12N2O3
Nabuser
RX_link
http://www.rxlist.com/cgi/generic2/nalidixicacid.htm
Nabuser
fda sheet
Nabuser
msds (material safety sheet)
Nabuser
Synthesis Reference
No information avaliable
Nabuser
Molecular Weight
232.235 g/mol
Nabuser
Melting Point
229.5 oC
Nabuser
H2O Solubility
100 mg/L
Nabuser
State
Solid
Nabuser
LogP
0.949
Nabuser
Dosage Forms
Suspension (250 mg/5 mL tsp); Tablets (1000 mg, 500 mg, 250 mg)
Nabuser
Indication
For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.
Nabuser
Pharmacology
Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. Nalidixic acid is bactericidal and is effective over the entire urinary pH range. Conventional chromosomal resistance to nalidixic acid taken in full dosage has been reported to emerge in approximately 2 to 14 percent of patients during treatment; however, bacterial resistance to nalidixic acid has not been shown to be transferable via R factor.
Nabuser
Absorption
Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.
Nabuser
side effects and Toxicity
ORAL (LD50): Acute: 1160 mg/kg [Rat]. 572 mg/kg [Mouse]. Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.
Nabuser
Patient Information
Nabuser
Organisms Affected
Enteric bacteria and other eubacteria